同種骨髄移植後移植片対宿主病に対するFK506投与2例に認めた糖代謝異常

書誌事項

タイトル別名
  • FK506-Induced Diabetes Mellitus in Two Patients Receiving Allogenic Bone Marrow Transplantation.

この論文をさがす

抄録

We experienced two patients who received allogenic bone marrow transplantation which induced diabetes mellitus (D.M.) following treatment with FK 506. In case 1, after three-week oral adminis trarionof FK 506 for chronic graft-versus-host disease (GVHD), the fasting blood sugar (FBS) level increased from 90 mg/dl to 156 mg/dl, and the C-peptide immunoreactivity (CPR) in the urine was concomitantly decreased to 9.7μg/day. At that time, the FK 506 concentration in the blood was 10 to 15ng/ml. Along with the reduction of the dose of FK 506, the CPR in the urine increased to 47.3yg/day. In case 2, after three-week intravenous administration of FK 506 for chronic GVHD, the FBS level increased from 80 mg/dl to 254 mg/dl and the urine CPR decreased from 256μg/day to 21.6μg/day. At that time, the FK 506 concentration was 15 to 20 ng/ml. Two weeks after readministration of CsA, the FBS level became 84 mg/dl. These findings indicate that D.M. is inducible in a dose-dependent manner in patients receiving a therapeutic dose of FK 506, while the FK 506-induced D. M. can be reversed by the reduction and/or discontinuation of the administra tionof FK 506.

収録刊行物

  • 糖尿病

    糖尿病 41 (2), 137-142, 1998

    一般社団法人 日本糖尿病学会

被引用文献 (2)*注記

もっと見る

参考文献 (17)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ